Cognition Therapeutics, Inc. (CGTX): Rega marang dodolan
The reliability of Cognition Therapeutics (CGTX) is based on the validation of oral drugs to combat brain degeneration and grant support. The company's market cap-to-revenue ratio, provided by the GURU.Markets platform, confirms the asset's dynamics, with the current level sitting around . The business advantage lies in synapse restoration, while the primary risk remains the success of clinical trials given the existing liquidity reserve.
Rincian analitis perusahaan Cognition Therapeutics (CGTX)
- rega lan prakiraan konsensus rega:
- data kapitalisasi bursa:
- data nilai buku modal saham:
- indikator beban kredit lan likuiditas emiten:
Utang Agregat marang Modal Cognition Therapeutics|CGTX - Utang jangka dawa marang modal|Rasio tanggungan utang jangka cendhak marang modal Cognition Therapeutics, Inc.|CGTX - Gunggung utang perusahaan|Utang-utang marang nilai buku Cognition Therapeutics|CGTX - Utang jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan Cognition Therapeutics|Rasio cepet cogrx.com
- indikator pendapatan resik lan kelipatan nilai:
CGTX - Bathi resik perusahaan|Bathi forward Cognition Therapeutics|CGTX - Pangali P/E|Rasio prakiraan rega marang bathi Cognition Therapeutics, Inc.|CGTX - Pangali rega marang bathi tumrap wutah|Pangali EV/EBITDA Cognition Therapeutics, Inc.|CGTX - Bathi operasional sadurunge ngurangi amortisasi|Bathi saben saham sajrone patang kuartal pungkasan Cognition Therapeutics|CGTX - Bathi resik saben saham (EPS TTM)|Owah-owahan bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan cogrx.com|CGTX - Wutah bathi ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Cognition Therapeutics
- indikator pendapatan dodolan lan penghasilan bisnis:
Analisis umum perusahaan:CGTX - cogrx.com
To minimize risks when establishing a long-term position, it is essential to analyze the price-to-sales ratio, which reflects the premium paid for every dollar of revenue. The current P/S valuation for Cognition Therapeutics (CGTX) demonstrates that the business value depends on the success of clinical trials for target molecules and FDA approval, determining the company's resilience within the neurodegenerative disease sector.
Pesaing Cognition Therapeutics
BIIB (Biogen) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S NBIX (Neurocrine Corp)|Regencell Bioscience - Rasio rega marang pendapatan|Axsome Therapeutics - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan ACAD (ACADIA Pharmaceuticals)|Xenon (XENE) - Rasio rega marang pendapatan|Rega marang dodolan Viking Therapeutics Inc (VKTX)|SUPN (Supernus Pharma) - Multiplikator P/S|CPRX: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S DNLI|Koefisien rega marang pendapatan Harmony Biosciences|Biohaven Ltd - Kapitalisasi marang pendapatan|Multiplikator P/S Amylyx Pharmaceuticals, Inc. AMLX|TRVI: Kapitalisasi marang pendapatan|Koefisien rega marang pendapatan Praxis Corp PRAX|AVXL: Multiplikator P/S|CBLL (ceribell.com) - Rasio rega marang pendapatan|PRTA (Prothena Corporation) - Multiplikator P/S|Kapitalisasi marang pendapatan alector.com (ALEC)|Rasio rega marang pendapatan Annexon, Inc. (ANNX)|OMER - Rega marang dodolan|Multiplikator P/S NGNE (Neurogene Inc)|AC Immune (ACIU) - Rega marang dodolan|Voyager Therapeutics Inc - Multiplikator P/S|Neumora (NMRA) - Kapitalisasi marang pendapatan|SCLX: Multiplikator P/S|TVGN - Koefisien rega marang pendapatan|ACOG (Alpha Cognition Inc) - Multiplikator P/S|Kapitalisasi marang pendapatan inhibikase.com (IKT)|Rasio rega marang pendapatan Cassava Sciences Inc (SAVA)|Koefisien rega marang pendapatan Assertio|Multiplikator P/S COYA (Coya Therapeutics, Inc.)|Kapitalisasi marang volume dodolan VTGN (VistaGen Therapeutics Inc)|OVID: Kapitalisasi marang pendapatan|ABOS: Rasio rega marang pendapatan|CervoMed (CRVO) - Rasio rega marang pendapatan|Rega marang dodolan Alterity Therapeutics Ltd (ATHE)|CLNN (Clene) - Multiplikator P/S|Rasio kapitalisasi marang pendapatan PEPG (PepGen)|Kapitalisasi marang pendapatan JUNS (Jupiter Neurosciences, Inc.)|Multiplikator P/S relmada.com (RLMD)|Rasio rega marang pendapatan Annovis Bio Corp ANVS|GRCE: Rasio kapitalisasi marang pendapatan|AIFF - Rasio rega marang pendapatan|KLTO (anewmeds.com) - Rasio kapitalisasi marang pendapatan|NRSN (NeuroSense Therapeutics Ltd.) - Kapitalisasi marang pendapatan|revivapharma.com - Rasio kapitalisasi pasar marang pendapatan|MTVA (metaviatx.com) - Multiplikator P/S|NRXS: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S HSDT|PASG - Rega marang dodolan|Multiplikator P/S NEUP (Neuphoria Therapeutics)|NERV: Rasio kapitalisasi marang pendapatan|ATHA: Kapitalisasi marang pendapatan|Addex Therapeutics Ltd - Kapitalisasi marang volume dodolan|Alzamend Neuro, Inc. (ALZN) - Rasio rega marang pendapatan|CYCN (Cyclerion Therapeutics Inc.) - Rasio rega marang pendapatan|Kapitalisasi marang pendapatan PTIX|KTTA: Rasio kapitalisasi pasar marang pendapatan|Kapitalisasi marang pendapatan CRGT (Cortigent Medical)|ATXI (Avenue Therapeutics, Inc.) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Brainstorm Cell Therapeutics, Inc. BCLI|Rasio kapitalisasi pasar marang pendapatan CARA|chromocell.com - Multiplikator P/S|Rasio rega marang dodolan ELYM|ITCI: Multiplikator P/S|Rega marang dodolan Longboard Pharmaceuticals, Inc. (LBPH)|Rasio rega marang pendapatan Marinus Pharmaceuticals, Inc.|NKGN: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S NRBO|SAGE: Rasio rega marang dodolan|Synaptogenix Inc. - Kapitalisasi marang pendapatan|Kapitalisasi marang volume dodolan TRVN (Trevena Inc.)|Vigil Neuroscience, Inc. - Multiplikator P/S|Anew Medical (WENA) - Kapitalisasi marang pendapatan|CERE (Cerevel Corp) - Kapitalisasi marang pendapatan
